JonesTrading analyst Justin Walsh reiterated a Buy rating on Lantheus today and set a price target of $70.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Justin Walsh has given his Buy rating due to a combination of factors that highlight Lantheus’s potential for growth and stability. The company’s recent earnings report showed that PYLARIFY revenue exceeded expectations, indicating a strong market position despite a year-over-year decline. Management’s confidence in stabilizing pricing and competing effectively suggests a positive outlook for future sales, particularly with the anticipated momentum in late 2026.
Furthermore, Lantheus’s strategic acquisitions from Life Molecular Imaging and Evergreen Theragnostics are expected to drive medium- to long-term growth, independent of current challenges. The company’s robust cash position and access to a significant line of credit provide financial flexibility to support pipeline expansion and capitalize on growth opportunities. These factors, combined with a risk-adjusted discounted cash flow valuation, underpin the $70 price target and reinforce the Buy recommendation.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $70.00 price target.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LNTH in relation to earlier this year.